Skip to main content

Ocular Therapeutix, Inc.

corporate_fare Company Profile

Ocular Therapeutix, Inc.

OCUL·NASDAQ·Life Sciences·CIK 0001393434

The company is an integrated biopharmaceutical company focused on retinal diseases. Its investigational product candidate, AXPAXLI (also known as OTX-TKI), is an axitinib intravitreal hydrogel based on its proprietary ELUTYX bioresorbable hydrogel-based formulation technology. AXPAXLI is in a Phase 3 registrational program for wet age-related macular degeneration (wet AMD), referred to as the SOL program, and another Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR), referred to as the HELIOS program. The company also uses its ELUTYX technology in its commercial product DEXTENZA, an FDA-approved corticosteroid. DEXTENZA treats ocular inflammation and pain after ophthalmic surgery in adults and pediatric patients, and ocular itching from allergic conjunctivitis in adults and pediatric patients aged two years or older. Additionally, the company has a product candidate, OTX-TIC, a travoprost intracameral hydrogel, which completed a Phase 2 clinical trial for open-angle glaucoma (OAG) or ocular hypertension (OHT). DEXTENZA and the company's clinical development candidates typically integrate previously FDA-approved therapeutic agents, such as small molecules, into ELUTYX to provide local programmed release in the eye. The ELUTYX hydrogel technology has been used in humans since 1992 and has been used in over five million patients across eight FDA-approved treatments, demonstrating its safety and effectiveness. DEXTENZA, the first and only FDA-approved drug-eluting intracanalicular insert, has been used in nearly 750,000 eyes since its launch, with reported adverse events in approximately 2 of every 10,000 patients.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for OCUL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for OCUL spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Ocular Therapeutix 10-Q: $94.8M Q3 Loss, $530.6M Cash, EyePoint Suit Settled
  • Ocular Therapeutix Posts $94.8M Q3 Loss; AXPAXLI NDA Still Set for Q4 2026
  • Ocular Therapeutix Posts $94.8M Third-Quarter Loss
  • FDA Pre-NDA Meeting Confirms AXPAXLI Path for Wet AMD, NDA on Track for Q4
  • Ocular Therapeutix Reports Q2 Results, Confirms Q4 AXPAXLI NDA Submission, Extends Cash Runway into 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$51.95M
Net Income
-$265.94M
Diluted EPS
-$1.42
Op. Cash Flow
-$204.88M
Free Cash Flow
-$216.89M
Gross Profit
$45.38M
Operating Income
-$270.02M
Cash & Equivalents
$737.06M
Debt / Equity
0.00×
Net Margin
-5.12×
Shares Outstanding
215.93M sh
Source: 10-K · filed 2026-02-05 · accession 0001104659-26-010664

Short Interest & Short Volume

10.14 days to cover

FINRA reported short interest of 28,998,345 shares in OCUL as of the October 30, 2026 settlement, a 0.8% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 34.9% of OCUL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)28,998,345 shares as of October 30, 2026
Change vs prior period▲ 0.8%
Days to cover10.14 at avg daily volume of 2,858,671
Daily short volume (FINRA facilities)34.9% of 1,102,341 shares on November 20, 2026
5-day average short volume37.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with O →
$5.6 +0.54% today
52-week range · as of 2026-11-09 $5.6 – $16.44
Market cap
$1.23B
Volume
2.9M (1.0× avg)
3-mo avg 3M
Live data · 2026-11-21 06:10 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OCUL - Latest Insights

OCUL
Nov 09, 2026, 7:19 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.20
Real-time Price: $5.60 info
Change: -$0.600 (-10%) info
Market Cap: $1.226B info
OCUL
Nov 09, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.06
Real-time Price: $5.60 info
Change: -$0.4598 (-8%) info
Market Cap: $1.226B info
OCUL
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.59
Real-time Price: $5.60 info
Change: -$0.990 (-15%) info
Market Cap: $1.226B info
OCUL
Sep 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.76
Real-time Price: $5.60 info
Change: -$5.16 (-48%) info
Market Cap: $1.226B info
OCUL
Aug 03, 2026, 7:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.27
Real-time Price: $5.60 info
Change: -$2.67 (-32%) info
Market Cap: $1.226B info
OCUL
Aug 03, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.35
Real-time Price: $5.60 info
Change: -$2.75 (-33%) info
Market Cap: $1.226B info
OCUL
Jun 12, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.89
Real-time Price: $5.60 info
Change: -$3.29 (-37%) info
Market Cap: $1.226B info
OCUL
May 05, 2026, 7:28 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.00
Real-time Price: $5.60 info
Change: -$4.40 (-44%) info
Market Cap: $1.226B info
OCUL
May 05, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $9.60
Real-time Price: $5.60 info
Change: -$4.00 (-42%) info
Market Cap: $1.226B info
OCUL
May 05, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $5.60 info
Change: -$4.05 (-42%) info
Market Cap: $1.226B info
OCUL
Apr 30, 2026, 5:23 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $9.39
Real-time Price: $5.60 info
Change: -$3.79 (-40%) info
Market Cap: $1.226B info
OCUL
Apr 30, 2026, 5:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $9.15
Real-time Price: $5.60 info
Change: -$3.55 (-39%) info
Market Cap: $1.226B info
OCUL
Apr 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $5.60 info
Change: -$3.16 (-36%) info
Market Cap: $1.226B info
OCUL
Feb 27, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.94
Real-time Price: $5.60 info
Change: -$3.34 (-37%) info
Market Cap: $1.226B info
OCUL
Feb 05, 2026, 7:58 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $8.90
Real-time Price: $5.60 info
Change: -$3.30 (-37%) info
Market Cap: $1.226B info
OCUL
Feb 05, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.00
Real-time Price: $5.60 info
Change: -$3.40 (-38%) info
Market Cap: $1.226B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets